Akari Therapeutics Expands ADC Pipeline with AKTX-102, Eyes First-in-Human Trials for AKTX-101 — Akari Therapeutics Plc

Event summary

Akari Therapeutics CEO Abizer Gaslightwala discussed the company’s expanded ADC pipeline and IP strategy in a Virtual Investor interview on February 11, 2026.
The company introduced AKTX-102, its second ADC candidate targeting CEACAM5-expressing solid tumors, highlighting the scalability of its PH1-powered ADC platform.
Akari’s lead program, AKTX-101, is advancing toward IND and CTA submissions with planned first-in-human studies by late 2026/early 2027.
The company emphasized the strategic importance of its growing patent estate for long-term value creation and potential partnering opportunities.

The big picture

Akari Therapeutics is positioning itself as a key player in the next-generation ADC space by leveraging its novel PH1 payload, which targets RNA splicing. The expansion of its pipeline with AKTX-102 underscores the company’s ability to generate multiple therapeutic programs, potentially broadening its addressable market in oncology. The strategic focus on intellectual property and partnering opportunities reflects a broader industry trend of biotech companies seeking to maximize value through both internal development and external collaborations.

What we're watching

Pipeline Scalability: How Akari’s PH1-powered ADC platform will support the development of additional differentiated therapeutic programs beyond AKTX-101 and AKTX-102.
Clinical Execution: The pace at which Akari can advance AKTX-101 through IND and CTA submissions and initiate first-in-human trials by late 2026/early 2027.
Partnering Opportunities: Whether Akari’s growing patent estate and expanded ADC pipeline will attract potential partners or licensing deals to accelerate its growth.